Project Grant R01CA295946
Award Date 8/28/25
Completion Date 7/31/30
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
- The University of North Carolina at Chapel Hill received a $159,540 Project Grant award from the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports a research project titled "Mechanistic Examination and Inhibitor Targeting of Nutrient Scavenging for the Treatment of Pancreatic Cancer." The project aims to investigate the role of macropinocytosis and autophagy, two metabolic processes that cancer cells use to obtain...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $698,008 to the University of Pennsylvania to conduct research on the regulation of histone propionylation and its relationship to metabolic changes in pancreatic ductal adenocarcinoma. The research aims to determine the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to regulate site-specific histone propionylation and gene expression,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- The federal Project Grant award in the amount of $159,304 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The award was granted to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on signaling pathways in tumoricidal macrophages in pancreatic cancer. The key objectives of the project include defining the role of deubiquitinases in regulating macrophage surface receptors that govern the recognition and phagocytosis...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Miami to support research into a novel immunotherapy approach for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a can regulate T cell exhaustion and restore anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC), which has a very low 5-year survival rate of 12%. The research will utilize the KPC mouse model of PDAC...
- This federal Project Grant award of $128,199 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the Regents of the University of Michigan to investigate the role of the lipid kinase PIKFYVE in regulating metabolic homeostasis in pancreatic ductal adenocarcinoma (PDAC). The research aims to 1) dissect PIKFYVE's function in PDAC metabolism, and 2) determine the mechanism and efficacy of combining PIKFYVE inhibition with KRAS-MAPK inhibition...
- This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...
- This Project Grant award of $147,486 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the University of Miami to investigate novel redox stress mechanisms that could inhibit KRAS-driven pancreatic ductal adenocarcinoma (PDAC). The project aims to define the role of the nucleotide pool-cleansing enzyme MTH1 in overcoming tumor-inhibitory reactive oxygen species (ROS) in KRAS-driven PDAC, which accounts for over 90% of PDAC cases. Preliminary data...
- The National Cancer Institute (NCI) awarded a $1,396,152 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Chicago. The grant, with a project period from December 5, 2024 to November 30, 2029, aims to examine the role of the BNIP3 gene and mitophagy (the selective degradation of mitochondria) in muscle atrophy during cancer cachexia, which is prevalent in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse...